Baseline hysteroscopic assessment of endometrium in asymptomatic postmenopausal women with estrogen receptor-positive breast cancer

Menopause

Volumn 20, Issue 1, 2013, Pages 64-71

  López, Daniel María Lubián ^a   Fernández, Yurena González ^a   Sánchez, Ángel Vilar ^a   Álvarez, María Iglesias ^a   Reynaldo, María Isabel López ^a   Delgado, Rafael Comino ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

Body mass index; Breast cancer; Endometrial pathology; Hysteroscopy; Postmenopausal

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENDOMETRIAL DISEASE; ENDOMETRIAL THICKNESS; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTEROSCOPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MORBIDITY; OBESITY; POSTMENOPAUSE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; TIME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CROSS-SECTIONAL STUDIES; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; HYSTEROSCOPY; MIDDLE AGED; POLYPS; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN; UTERINE DISEASES;

EID: 84872068471     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318259eaf3     Document Type: Article

References (57)

1. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant therapy for breast cancer. J Natl Cancer Inst 1996; 88:332-334.
2. Willet WC, Rockhill B, Hankinson SE, Hunter DJ, Colditz GA. Epidemiology and non genetic causes of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast, 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:175-220.
3. Brinton LA, Hoover RN. Epidemiology of gynecological cancers. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:3-27.
4. Kinsinger LA, Harris R, Lewis C, Woddell M. Chemoprevention of breast cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:59-69.
5. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat 1998;48:81-85.
6. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen J, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664.
7. Cohen J, Rosen DJD, Altaras M, et al. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroids overgrowth. Br J Cancer 1994; 69:620-621.
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer (Cochrane review). Cochrane Database Syst Rev 2001;1: CD000486.
9. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475-1478.
10. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 2002;101:58-63.
11. Berliere M, Radikov G, Galant C, Piette P, Marbaix E, Donnez J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer 2000;36:S35-S36.
12. Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol 2003;90:382-386.
13. Lubián López DM, González Fernández Y, Rodríguez Rodríguez B, Orihuela López FM, Comino Delgado R. Value of the progesterone test in screening for endometrial pathology in asymptomatic postmenopausal women receiving treatment with tamoxifen. Menopause 2010;17:487-493.
14. Willen R, Lindahl B, Andolf E, Ingvar C, Liedman R, Ranstam J. Histopathologic findings in thickened endometria, as measured by ultrasound in asymptomatic, postmenopausal breast cancer patients on various adjuvant treatment including tamoxifen. Anticancer Res 1998;18:667-676.
15. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998;91:40-44.
16. Gerber B, Krouse A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000;18:3464-3470.
17. Neven P, DeMuyider X, VanBelle Y, et al. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 1998;351:36.
18. Goncalves MAG, Goncalves NJ, Matias MM, Nazario ACP, Rodrigues DeLima G, Baracat EC. Hysteroscopic evaluation of the endometrium of postmenopausal patients with breast cancer before and after tamoxifen use. Int J Gynecol Obstet 1999;66:273-279.
19. Duffy S, Jackson, TL, Lansdown M, et al. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. BJOG 2003;110:1099-2006.
20. Garuti G, Cellani F, Centinaio G, Sita G, Nalli G, Luerti M. Baseline endometrial assessment before tamoxifen for breast cancer in asymptomatic menopausal women. Gynecol Oncol 2005;98:63-67.
21. Garuti G, Grossi F, Centinaio G, Sita G, Nalli G, Luerti M. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. Eur J Obstet Gynecol Reprod Biol 2007; 132:101-106.
22. Bettocchi S, Ceci O, Di Venere R, et al. Advanced operative office hysteroscopy without anaesthesia: analysis of 501 cases treated with a 5 Fr bipolar electrode. Hum Reprod 2002;17:2435-2438.
23. Garuti G, Cellani F, Centinaio G, Montanari G, Nalli G, Luerti M. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol 2006;103:599-603.
24. Bertelli G, Hall E, Ireland E, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled trial of exemestane versus continued tamoxifen after 23 years tamoxifen. Ann Oncol 2010; 21:498-505.
25. World Medical Association Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926.
26. Garuti G, Sambruni I, Colonnelli M, Luerti M. Accuracy of hysteroscopy in predicting histopathology of endometrium in 1500 women. J Am Assoc Gynecol Laparosc 2001;8:207-213.
27. World Health Organization classification of tumours. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:218-230.
28. Fleischer AC, Wheeler JE, Lindsay I, et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. Am J Obstet Gynecol 2001;184:70-74.
29. Archer DF, McIntyre-Seltman K, Wilborn WW, et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol 1991;165:317-322.
30. Dreisler E, Stampe Sorensen S, Ibsen PH, Lose G. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20-74 years. Ultrasound Obstet Gynecol 2009;33:102-108.
31. Juneja M, Jose R, Kekre AN, Viswanathan L, Seshadri L. Tamoxifeninduced endometrial changes in postmenopausal women with breast carcinoma. Int J Gynecol Obstet 2002;76:279-284.
32. Duffy S, Jackson TL, LansdownM, et al. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2005;110:1099-2006.
33. Seoud M, Shamseddine A, Khalil A, et al. Tamoxifen and endometrial pathology. A prospective study. Gynecol Oncol 1999;75:15-19.
34. Andía D, Lafuente P, Matorras R, Usandizaga JM. Uterine side effects of treatment with tamoxifen. Eur J Obstet Gynecol Reprod Biol 2000;92: 235-240.
35. Nagele F, O'Connor H, Davies A, Badawy A, Mohamed H, Magos A. 2500 outpatient diagnostic hysteroscopies. Obstet Gynecol 1996;88:87-92.
36. Garuti G, Cellani F, Grossi F, Colonnelli M, Centinaio G, Luerti M. Saline infusion sonography and office hysteroscopy to assess endometrial morbidity associated with tamoxifen intake. Gynecol Oncol 2002;86:323-329.
37. de Kroon CD, de Bock GH, Dieben SW, Jansen FW. Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-analysis. BJOG 2003;110:938-947.
38. Gumus II, Keskin EA, Kili0 E, Aker A, Kafali H, Turhan NO. Diagnostic value of hysteroscopy and hysterosonography in endometrial abnormalities in asymptomatic postmenopausal women. Arch Gynecol Obstet 2008;278:241-244.
39. Sherman ME, Mazur MT, Kurman RJ. Benign diseases of the endometrium. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. New York, NY: Springer-Verlag; 2002:421-466.
40. Kremer C, Barik S, Duffy S. Flexible outpatient hysteroscopy without anaesthesia: a safe, successful and well tolerated procedure. Br J Obstet Gynaecol 1998;105:672-676.
41. Bakkum-Gamez JN, Laughlin SK, Jensen JR, Akogyeram CO, Pruthi S. Challenges in the gynecologic care of premenopausal women with breast cancer. Mayo Clin Proc 2011;86:229-240.
42. Antunes A Jr, Costa-Paiva L, Arthuso M, Costa JV, Pinto-Neto AM. Endometrial polyps in pre-and postmenopausal women: factors associated with malignancy. Maturitas 2007;57:415-421.
43. Costa-Paiva L, Godoy C, Antunes A, Caseiro J, Arthuso M, Pinto-Neto A. Risk of malignancy in endometrial polyps in premenopausal and postmenopausal women according to clinicopathologic characteristics. Menopause 2011;18:1278-1282.
44. Hileeto D, Fadare O, Martel M, Zheng W. Age dependent association of endometrial polyps with increased risk of cancer involvement. World J Surg Oncol 2005;3:8.
45. Savelli L, De Iacco P, Santini D, et al. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. Am J Obstet Gynecol 2003;188:927-931.
46. Fernandez-Parra J, Rodriguez Oliver A, Lopez Criado S, Parrilla Fernandez F, MontoyaVentoso F. Hysteroscopic evaluation of endometrial polyps. Int J Gynaecol Obstet 2006;95:144-148.
47. Ben-Arie A, Goldchmit C, Laviv Y, et al. The malignant potential of endometrial polyps. Eur J Obstet Gynecol Reprod Biol 2004;115: 206-210.
48. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000;356:881-887.
49. Cohen I. Endometrial polyps in pre-and postmenopausal women: factors associated with malignancy. Maturitas 2008;59:99-100.
50. Chang J, Powles TJ, Ashley SE, Iveson T, Oregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat 1998;48:81-85.
51. Ramondetta LM, Sherwood JB, Dunton CJ, Palazzo JP. Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol 1999;180:340-341.
52. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007;369: 559-570.
53. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-776.
54. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011;377:321-331.
55. Berlière M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998;91:40-44.
56. Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27: 3235-3258.
57. Marchesoni D, Driul L, Fabiani G, Di Loreto C, Cataldi P, Mozzanega B. Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen. Int J Gynaecol Obstet 2001;75:257-262.